机构：[1]Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab South China, Hong Kong, Peoples R China[2]Jilin Prov Canc Hosp, Changchun, Jilin, Peoples R China[3]Third Mil Med Univ, Affiliated Hosp 1, Dept Resp Med, Chongqing, Peoples R China[4]Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea[5]Kindai Univ Hosp, Osaka, Japan[6]Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan[7]Catalan Inst Oncol, Barcelona, Spain[8]SFJ Pharmaceut, Pleasanton, CA USA[9]Pfizer Inc, MapleTree Business City, Singapore, Singapore[10]Pfizer Oncol, La Jolla, CA USA[11]Pfizer Biopharmaceut Grp, Hong Kong, Peoples R China[12]Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China广东省人民医院[13]Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China广东省人民医院
第一作者机构：[1]Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab South China, Hong Kong, Peoples R China
推荐引用方式(GB/T 7714)：
Mok T. S. K.,Cheng Y.,Zhou X.,et al.Safety and efficacy of dacomitinib for EGFR plus NSCLC in the subgroup of Asian patients from ARCHER 1050[J].ANNALS OF ONCOLOGY.2019,30:
APA：
Mok, T. S. K.,Cheng, Y.,Zhou, X.,Lee, K. H.,Nakagawa, K....&Wu, Y-L..(2019).Safety and efficacy of dacomitinib for EGFR plus NSCLC in the subgroup of Asian patients from ARCHER 1050.ANNALS OF ONCOLOGY,30,
MLA：
Mok, T. S. K.,et al."Safety and efficacy of dacomitinib for EGFR plus NSCLC in the subgroup of Asian patients from ARCHER 1050".ANNALS OF ONCOLOGY 30.(2019)
医学